Table 3.
Outcome | Odds ratio (95% CI) for CTD-associated PAH vs. idiopathic PAH | P |
---|---|---|
Infection | 1.65 (1.31–2.08) | <0.001 |
Headache | 0.85 (0.65–1.13) | 0.26 |
Musculoskeletal | 1.13 (0.87–1.48) | 0.36 |
Edema | 1.12 (0.85–1.48) | 0.42 |
Rash | 0.89 (0.62–1.29) | 0.54 |
Bleeding | 1.49 (1.08–2.06) | 0.021 |
Nausea/vomiting | 1.10 (0.78–1.54) | 0.59 |
Dizziness | 1.09 (0.78–1.52) | 0.62 |
Cough | 0.99 (0.66–1.49) | 0.98 |
Dyspnea | 1.33 (0.91–1.93) | 0.14 |
Odds ratios with 95% confidence intervals (95% CIs) were determined in analyses adjusted for age, sex, race, treatment (drug versus placebo), study, body mass index, baseline 6-minute walk distance, baseline World Health Organization functional class, baseline hemodynamics (cardiac index, mean pulmonary arterial pressure, right atrial pressure), and baseline laboratory values (creatinine and hemoglobin levels). CTD-associated PAH = connective tissue disease–associated pulmonary arterial hypertension.